[1]朱亭 邓月珍 季正香 董林 成兴波.利拉鲁肽对初诊肥胖2型糖尿病患者血清 nesfatin-1和炎性指标的影响[J].国际内分泌代谢杂志,2018,38(06):366-369.[doi:10.3760/cma.j.issn.1673-4157.2018.06.002]
　Zhu Ting,Deng Yuezhen,Ji Zhengxiang,et al.Effects of liraglutide on level of serum nesfatin-1 and inflammatory factors in newly diagnosed obese patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(06):366-369.[doi:10.3760/cma.j.issn.1673-4157.2018.06.002]
点击复制

利拉鲁肽对初诊肥胖2型糖尿病患者血清 nesfatin-1和炎性指标的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年06期
页码:
366-369
栏目:
论著
出版日期:
2018-11-20

文章信息/Info

Title:
Effects of liraglutide on level of serum nesfatin-1 and inflammatory factors in newly diagnosed obese patients with type 2 diabetes mellitus
作者:
朱亭 邓月珍 季正香 董林 成兴波
作者单位:225400 扬州大学医学院附属泰兴市人民医院内分泌科
Author(s):
Zhu Ting;  Deng Yuezhen;  Ji Zhengxiang;  Dong Lin;  Cheng Xingbo
Department of Endocrinology & Metabolism, The Affiliated Taixing People's Hospital of Medical College, Taixing 225400, China
关键词:
利拉鲁肽;  Nesfatin-1;  炎症;  2型糖尿病;  肥胖
Keywords:
Liraglutide;  Nesfatin-1;  Inflammation;  Type 2 diabetes mellitus;  Obesity
DOI:
10.3760/cma.j.issn.1673-4157.2018.06.002
摘要:
目的 探讨利拉鲁肽对初诊肥胖2型糖尿病(T2DM)患者血清nesfatin-1以及炎性指标的影响。方法 选取2015年6月至2017年5月在扬州大学医学院附属泰兴人民医院内分泌科门诊新诊断的肥胖T2DM患者66例(肥胖T2DM组)以及体检中心的健康体检者40名(健康对照组),肥胖T2DM组使用利拉鲁肽皮下注射治疗3个月,比较治疗前、后血清nesfatin-1、白细胞介素-6(IL-6)、单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子-α(TNF-α)水平、体重指数、空腹血糖、HbA1c,分析nesfatin-1与炎性指标的相关性。结果 治疗前,与健康对照组相比,肥胖T2DM组血清nesfatin-1水平明显下降(t=5.343,P<0.01),IL-6、TNF-α、MCP-1水平均显著升高(t=-13.358、-3.211、3.622,P均<0.01),且nesfatin-1与IL-6(r=-0.38,P=0.07)、MCP-1(r=-0.88,P<0.01)、TNF-α(r=-0.68,P<0.01)呈负相关; 经利拉鲁肽治疗后,肥胖T2DM组空腹血糖、HbA1c、体重指数以及血清IL-6、MCP-1、TNF-α水平均较治疗前下降(t=6.735、6.702、6.314、3.622、3.897、11.191,P均<0.01),而nesfatin-1水平较治疗前升高(t=-13.560,P<0.01)。结论 利拉鲁肽不仅上调肥胖T2DM患者血清nesfatin-1水平,而且具有潜在的抗炎作用。
Abstract:
Objective To investigate the effects of liraglutide on level of serum nesfatin-1 and inflammatory factors in newly diagnosed obese patients with type 2 diabetes mellitus(T2DM).Methods Sixty-six outpatients with newly diagnosed obese T2DM(obese T2DM group)and 40 healthy subjects(healthy control group)in the physical examination center from Jun 2015 to May 2017 were enrolled in this study. The obese T2DM group received a subcutaneous injection with liraglutide for three months. Serum nesfatin-1, interleukin-6(IL-6), monocyte chemoattractant protein-1(MCP-1), tumor necrosis factor-α(TNF-α), body mass index(BMI), fasting plasma glucose(FPG), and HbA1c were compared before and after treatment. Furthermore, the correlation of nesfatin-1 with inflammtory factors was analyzed.Results Before treatment, compared with healthy control group, serum nesfatin-1 in obese T2DM group was significantly decreased(t=5.343, P<0.01)and serum IL-6, TNF-αand MCP-1 were significantly increased(t=-13.358, -3.211, 3.622, all P<0.01). The level of nesfatin-1 in obese T2DM subjects was negatively correlated with the level of IL-6, MCP-1 and TNF-α(r=-0.38, P=0.07; r=-0.88, P<0.01; r=-0.68,P<0.01). After treatment with liraglutide, the levels of FPG, HbA1c, BMI, IL-6, MCP-1 and TNF-α were significantly decreased(t=6.735, 6.702, 6.314, 3.622, 3.897, 11.191, all P<0.01), while the level of nesfatin-1 was significantly increased(t=-13.560, P<0.01).Conclusion Liraglutide can not only effectively improve the level of serum nesfatin-1 in obese patients with T2DM, but also have potential anti-inflammatory effect.

参考文献/References:


[1] Saltiel AR,Olefsky JM.Inflammatory mechanisms linking obesity and metabolic disease[J].J Clin Invest,2017,127(1):1-4.DOI:10.1172/JCI92035.
[2] Donath MY,Shoelson SE.Type 2 diabetes as an inflammatory disease[J].Nat Rev Immunol,2011,11(2):98-107.DOI:10.1038/nri2925.
[3] Algul S,Ozkan Y,Ozcelik O.Serum nesfatin-1 levels in patients with different glucose tolerance levels[J].Physiol Res,2016,65(6):979-985.
[4] Blüher M.Adipose tissue dysfunction contributes to obesity related metabolic diseases[J].Best Pract Res Clin Endocrinol Metab,2013,27(2):163-177.DOI:10.1016/j.beem.2013.02.005.
[5] Grams J,Garvey WT.Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action[J].Curr Obes Rep,2015,4(2):287-302.DOI:10.1007/s13679-015-0155-x.
[6] Guarner V,Rubio-Ruiz ME.Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease[J].Interdiscip Top Gerontol,2015,40:99-106.DOI:10.1159/000364934.
[7] Kuhre RE,Holst JJ,Kappe C.The regulation of function, growth and survival of GLP-1-producing L-cells[J].Clin Sci(Lond),2016,130(2):79-91.DOI:10.1042/CS20150154.
[8] Ayada C,Toru Ü,Korkut Y. Nesfatin-1 and its effects on different systems[J].Hippokratia,2015,19(1):4-10.
[9] Ramanjaneya M,Addison M,Randeva HS.Possible role of NUCB2/nesfatin-1 in adipogenesis[J].Curr Pharm Des,2013,19(39):6976-6980.
[10] Shimizu H,Osaki A.Nesfatin/nucleobindin-2(NUCB2)and glucose homeostasis[J].Curr Hypertens Rev,2014,[Epub ahead of print].
[11] Copps KD,White MF.Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2[J].Diabetologia,2012,55(10):2565-2582.DOI:10.1007/s00125-012-2644-8.
[12] Tanaka T,Itoh H,Doi K,et al.Down regulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones[J].Diabetologia,1999,42(6):702-710.
[13] Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis[J].Circulation,2002,105(9):1135-1143.
[14] Pickup JC.Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes[J].Diabetes Care,2004,27(3):813-823.
[15] Parthsarathy V,Hölscher C.The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain[J].Eur J Pharmacol,2013,700(1-3):42-50.DOI:10.1016/j.ejphar.2012.12.012.
[16] Ozturk CC,Oktay S,Yuksel M,et al.Anti-inflammatory effects of nesfatin-1 in rats with acetic acid - induced colitis and underlying mechanisms[J].J Physiol Pharmacol,2015,66(5):741-750.
[17] Kolgazi M,Cantali-Ozturk C,Deniz R,et al.Nesfatin-1 alleviates gastric damage via direct antioxidant mechanisms[J].J Surg Res,2015,193(1):111-118. DOI:10.1016/j.jss.2014.06.057.
[18] Tang CH,Fu XJ,Xu XL,et al.The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain[J].Peptides,2012,36(1):39-45.DOI:10.1016/j.peptides.2012.04.014.

备注/Memo

备注/Memo:
作者单位:225400 扬州大学医学院附属泰兴市人民医院内分泌科
通信作者:成兴波,Email:seaborg@tom.com
更新日期/Last Update: 2018-12-30